Nuformix has today received the results from pre-clinical studies for its NX006 product range.
NX006 is a leading treatment in pain management with annual sales exceeding £340m in 2009. However, patients treated using the currently marketed form require a high daily dosage of over 3000 mg of this very low solubility API.
In-vivo testing of the new solid forms of NX006 created by Nuformix demonstrate an increase of up to 220% in bioavailability. Across the range of forms studied, the results conclusively demonstrate that dramatic reductions in patient dosage are achievable, as are improved release profiles and more cost-effective manufacturing.
These options are made possible by Nuformix simply via re-engineering of the solid form and were expected following significant physical property changes when compared to the parent compound.
Nuformix have therefore completed critical steps in its strategy to discover, scale-up and validate vastly improved forms of currently marketed drug products and is currently seeking collaborative partnerships to enable market approval of this product.